AB-343   Click here for help

GtoPdb Ligand ID: 13659

PDB Ligand
Compound class: Synthetic organic
Comment: AB-343 is a small molecule reversible inhibitor of coronavirus main protease (Mpro; 3CLpro) [2]. It has reported activity at the homologous proteases from a range of coronaviruses that infect humans (indicating pan-coronavirus activity), including SARS-CoV, SARS-CoV-2, and MERS-CoV, but is inactive against a set of human proteases. This compound and related analogues are claimed in patent WO2023055702A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 131.46
Molecular weight 577.59
XLogP 3.88
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1(C)C[C@H](C[C@@H](C=N)NC(=O)[C@@H]2[C@@H]3CC[C@@H](CC3(F)F)N2C(=O)[C@@H](CC4CCC4)NC(=O)C(F)(F)F)C(=O)N1
Isomeric SMILES N=C[C@H](C[C@@H]1C(NC(C1)(C)C)=O)NC(=O)[C@H]2N([C@@H]3CC([C@H]2CC3)(F)F)C([C@@H](CC4CCC4)NC(C(F)(F)F)=O)=O
InChI InChI=1S/C26H36F5N5O4/c1-24(2)10-14(20(37)35-24)9-15(12-32)33-21(38)19-17-7-6-16(11-25(17,27)28)36(19)22(39)18(8-13-4-3-5-13)34-23(40)26(29,30)31/h12-19,32H,3-11H2,1-2H3,(H,33,38)(H,34,40)(H,35,37)/t14-,15-,16-,17-,18+,19-/m0/s1
InChI Key KLQWCIBSZOJHLB-VIUKOLAESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Chen S, Cole AG, Dorsey BD, Fan Y, Gotchev DB, Kultgen SG, Limdstrom AR, Nguyen D, Sofia MJ, Vega MM et al.. (20236)
Main protease (m pro) inhibitors and methods using same.
Patent number: WO2023055702A1. Assignee: Arbutus Biopharma Corporation. Priority date: 27/09/2022. Publication date: 06/04/2023.
2. McGovern-Gooch KR, Mani N, Gotchev D, Ardzinski A, Kowalski R, Sheraz M, Micolochick Steuer HM, Tercero B, Wang X, Wasserman A et al.. (2024)
Biological characterization of AB-343, a novel and potent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activity.
Antiviral Res, 232: 106038. [PMID:39577571]